@article{3031626,
    title = "MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study
of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable
stage IIIB-IVM1c melanoma (MEL)",
    author = "Ribas, A. and Chesney, J. and Long, G. V. and Kirkwood, J. M. and and Dummer, R. and Puzanov, I. and Hoeller, C. and Gajewski, T. F. and and Gutzmer, R. and Rutkowski, P. and Demidov, L. and Arenberger, P. and and Shin, S. J. and Ferrucci, P. F. and Diede, S. J. and Anderson, J. R. and and Treichel, S. and Chan, E. and Hodi, F. S. and Gogas, H. J.",
    journal = "Annals of Oncology",
    year = "2021",
    volume = "32",
    number = "5",
    pages = "S868-S869",
    publisher = "Elsevier",
    issn = "0923-7534, 1569-8041",
    doi = "10.1016/j.annonc.2021.08.1422"
}